Evidence map›Paper›PMID 29152559›Full record

ArticleAnnals of clinical pathology2017

Olgary Figueroa-Santiago, Ana M Espino

Open access · greenAbstract read
In one paragraph

Article in Annals of clinical pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Pathogens (Basel, Switzerland) · 2024
    Article
  2. Journal of proteome research · 2022
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Olgary Figueroa-SantiagoDepartment of Microbiology, University of Puerto Rico-Medical Sciences Campus, USA.
Ana M EspinoDepartment of Microbiology, University of Puerto Rico-Medical Sciences Campus, USA.
University of Puerto Rico, Medical Sciences Campus · PR

Funding

RISE Option III: MBRS RISE at the UPR Medical Sciences CampusR25GM061838 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CADILLA, CARMEN LYDIA · 2000 to 2021
$25.5M
13: The Indiana IAIMS InitiativeG08LM008232 · NLM · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI OVERHAGE, JOSEPH MARCUS · 2004 to 2007
$1.3M
Towards a vaccine against Fasciola hepatica using FhSAP2 as an antigenSC1AI096108 · NIAID · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI ESPINO, ANA M · 2011 to 2013
$662k
NIAID NIH HHS SC1 AI096108NIGMS NIH HHS R25 GM061838NLM NIH HHS G08 LM008232
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Excretory-secretory productsFasciola hepaticaFatty acid binding proteinInnate immunityToll-like receptors

Identifiers

PMID29152559
PMCPMC5690573
OpenAlexW3022559015

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.